Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439238 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL30771497 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL10201896 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12 | |
| SCHEMBL8591641 | 0.83 | CA12 (0.43) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL1531190 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12TSHR | |
| SCHEMBL14405592 | 0.80 | CA1 (0.35) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL4607095 | 0.80 | CA1 (0.35) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL4607090 | 0.80 | CA1 (0.35) | SMN1; SMN2CA14CA12CA7CA9 | |
| SCHEMBL1279107 | 0.79 | ALDH1A1 (0.37) | TSHR | |
| SCHEMBL7955435 | 0.79 | CA12 (0.32) | SMN1; SMN2CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753806-A | Heterogeneous synthetic method and application of Ritonavir intermediate | 厦门市蔚嘉化学科技有限公司 | 2016-07-13 | — | — | CN | claimed |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| CN-113286792-B | N-chromen-4-one containing derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3894402-B1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022030589-A1 | LIGAND CONTAINING MONODENTATE COORDINATION UREA COMPOUND, AND BORYLATION CATALYST CONTAINING SAME | 国立大学法人北海道大学 | 2022-02-10 | — | — | WO | disclosed |
| CN-113286792-A | N-containing chromen-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-112020500-A | Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase | 拉文纳制药公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3696171-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-1267291-A | Novel farnesyl protein transferase inhibitors of N-substituted ureas | SCHERING CORP (US) | 2000-09-20 | — | — | CN | disclosed |
| WO-2000035885-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1998046615-A1 | METALLOCENE AMINO ACID AND PEPTIDE COMPLEXES | TARGOR GMBH (DE) | 1998-10-22 | — | — | WO | disclosed |
| US-5807870-A | SIDE EFFECT REDUCTION | BIOMEGA BOEHRINGER INGELHEIM RESEARCH LTD. (CA) | 1998-09-15 | — | — | US | disclosed |
| US-5614533-A | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) | 1997-03-25 | — | — | US | disclosed |
| EP-0560268-B1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-04 | — | — | EP | disclosed |
| CN-1096293-A | Replacement pipecolinic acid derivative as the hiv protease inhibitor | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1994-12-14 | — | — | CN | disclosed |
| WO-1993018003-A1 | SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | disclosed |
| EP-0560268-A1 | Substituted pipecolinic acid derivatives as HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR0B1, CYP7A1 | SMN1; SMN2 2216/4885CA14 1974/4885CA12 2723/4885 |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1B, PIP5K1A, PIP5K1C | SMN1; SMN2 2821/4885CA14 4858/4885CA12 4875/4885 |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1B, PIP5K1A, PIP5K1C | SMN1; SMN2 2439/4885CA14 4841/4885CA12 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.